perhexiline has been researched along with Left Ventricular Hypertrophy in 3 studies
Perhexiline: 2-(2,2-Dicyclohexylethyl)piperidine. Coronary vasodilator used especially for angina of effort. It may cause neuropathy and hepatitis.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The presence and extent of left ventricular hypertrophy (LVH) is a major determinant of symptoms in patients with hypertrophic cardiomyopathy (HCM)." | 7.01 | Randomized controlled trial of perhexiline on regression of left ventricular hypertrophy in patients with symptomatic hypertrophic cardiomyopathy (RESOLVE-HCM trial). ( Ananthakrishna, R; Binda, G; Foote, J; Horowitz, JD; Lee, SL; Mangoni, AA; Sallustio, BC; Selvanayagam, JB; Semsarian, C; Woodman, R, 2021) |
| "Perhexiline has been shown to be an effective anti-anginal agent due to its metabolic modulation properties by inhibiting the uptake of free fatty acids into the mitochondrion, and thereby promoting a more efficient carbohydrate-driven myocardial metabolism." | 6.80 | Multicentre double-blind randomized controlled trial of perhexiline as a metabolic modulator to augment myocardial protection in patients with left ventricular hypertrophy undergoing cardiac surgery. ( Bhudia, S; Drury, NE; Freemantle, N; Frenneaux, M; Graham, TR; Green, D; Howell, NJ; Lewis, M; Mascaro, J; Oelofse, T; Pagano, D; Ranasinghe, AM; Rooney, SJ; Senanayake, EL; Wilson, IC, 2015) |
| "The presence and extent of left ventricular hypertrophy (LVH) is a major determinant of symptoms in patients with hypertrophic cardiomyopathy (HCM)." | 3.01 | Randomized controlled trial of perhexiline on regression of left ventricular hypertrophy in patients with symptomatic hypertrophic cardiomyopathy (RESOLVE-HCM trial). ( Ananthakrishna, R; Binda, G; Foote, J; Horowitz, JD; Lee, SL; Mangoni, AA; Sallustio, BC; Selvanayagam, JB; Semsarian, C; Woodman, R, 2021) |
| "Perhexiline has been shown to be an effective anti-anginal agent due to its metabolic modulation properties by inhibiting the uptake of free fatty acids into the mitochondrion, and thereby promoting a more efficient carbohydrate-driven myocardial metabolism." | 2.80 | Multicentre double-blind randomized controlled trial of perhexiline as a metabolic modulator to augment myocardial protection in patients with left ventricular hypertrophy undergoing cardiac surgery. ( Bhudia, S; Drury, NE; Freemantle, N; Frenneaux, M; Graham, TR; Green, D; Howell, NJ; Lewis, M; Mascaro, J; Oelofse, T; Pagano, D; Ranasinghe, AM; Rooney, SJ; Senanayake, EL; Wilson, IC, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Ananthakrishna, R | 1 |
| Lee, SL | 1 |
| Foote, J | 1 |
| Sallustio, BC | 1 |
| Binda, G | 1 |
| Mangoni, AA | 1 |
| Woodman, R | 1 |
| Semsarian, C | 1 |
| Horowitz, JD | 2 |
| Selvanayagam, JB | 1 |
| Senanayake, EL | 1 |
| Howell, NJ | 1 |
| Ranasinghe, AM | 1 |
| Drury, NE | 1 |
| Freemantle, N | 1 |
| Frenneaux, M | 1 |
| Oelofse, T | 1 |
| Green, D | 1 |
| Wilson, IC | 1 |
| Rooney, SJ | 1 |
| Mascaro, J | 1 |
| Graham, TR | 1 |
| Bhudia, S | 1 |
| Lewis, M | 1 |
| Pagano, D | 1 |
| Chirkov, YY | 1 |
| Kennedy, JA | 1 |
| Sverdlov, AL | 1 |
1 review available for perhexiline and Left Ventricular Hypertrophy
| Article | Year |
|---|---|
Modulation of myocardial metabolism: an emerging therapeutic principle.
Topics: Acetanilides; Amiodarone; Cardiovascular Agents; Heart Failure; Humans; Hypertrophy, Left Ventricula | 2010 |
2 trials available for perhexiline and Left Ventricular Hypertrophy
| Article | Year |
|---|---|
Randomized controlled trial of perhexiline on regression of left ventricular hypertrophy in patients with symptomatic hypertrophic cardiomyopathy (RESOLVE-HCM trial).
Topics: Adult; Cardiomyopathy, Hypertrophic; Cardiovascular Agents; Double-Blind Method; Echocardiography; F | 2021 |
Multicentre double-blind randomized controlled trial of perhexiline as a metabolic modulator to augment myocardial protection in patients with left ventricular hypertrophy undergoing cardiac surgery.
Topics: Aged; Cardiotonic Agents; Combined Modality Therapy; Coronary Artery Bypass; Double-Blind Method; El | 2015 |